The FDA recently approved perampanel (Fycompa) for the treatment of partial-onset seizures in patients 12 years and older. Perampanel is a highly selective glutamate antagonist, blocking the action of the neurotransmitter glutamate. The most common adverse effects include dizziness, vertigo, weight gain, blurred vision, and excessive sleep. Due to serious neuropsychiatric events (irritability, aggression, paranoia, anxiety), there will be a black box warning on the drug labelalerting physicians about this risk. A patient medication guide will also be provided to patients. What other medications are indicated for partial-onset seizures?
To find out more, please read the article in Reuters.